GNFTF News and Press, Genfit Ord From 12/17/18

Recently, Conatus Pharmaceuticals ( CNAT ) reported results from a phase 2b study known as ENCORE-PH. It noted that this study had failed to meet on the primary endpoint; however, there are still many shots on goal left. This is why I believe that this biotech has a chance to recover. For st...

Nothing can dim the light that shines from within - Maya Angelou Introduction Genfit ( GNFTF ) and GenKyoTex (GKTX.PA) are both French clinical-stage biopharmaceutical companies with unique and different therapeutic approaches to primary biliary cholangitis ((PBC)). I previously affirm...

Recently, Genfit ( OTCPK:GNFTF ) announced that it had received positive results treating patients with primary biliary cholangitis (PBC). These positive results were obtained using the company's NASH drug elafibranor. Positive results from the study were obtained after patients were tre...

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Pfizer Suffers Setback With Partner Merck KGaA On PD-L1 Drug Bavencio News: Recently, Pfizer ( PFE ) and Merck KGaA ( MKKGY ) announced that they...

Any man or institution that tries to rob me of my dignity will lose - Nelson Mandela Introduction The once dormant clinical research and development of therapies for the non-viral liver disease, NASH, is now characterized by intense competition with over 30 innovative drug candidate...

GENFIT SA ( OTCPK:GNFTF ) plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares in the United States. More news on: Genfit, Read more ...

Introduction European biotech stocks have a lower valuation in general than American biotechs. It is an observation that many sector followers have already made. In my opinion the cause can be found in the overall ecosystem for biotech. In the United States there is more appetite for this pa...

In this article, I'd like to continue my recent focus on some of the major players in the NASH drug development race. Genfit (OTCPK: GNFTF ), a France-based biotech, is one of the firms farthest along in the development process - it is currently in process of conducting a Phase 3 trial to eva...

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high un...

In June, Galmed (NASDAQ: GLMD ) announced data from its Phase 2b trial evaluating its lead drug candidate Aramchol's ability to reduce liver fat in patients with NASH fibrosis . Though the drug failed its primary endpoint, it did demonstrate a moderate ability to reduce liver fat, improve ...